These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 8586461)

  • 21. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
    Reardon DA; Zalutsky MR; Bigner DD
    Expert Rev Anticancer Ther; 2007 May; 7(5):675-87. PubMed ID: 17492931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination.
    Yu JS; Luptrawan A; Black KL; Liu G
    Clin Neurosurg; 2006; 53():345-51. PubMed ID: 17380773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies in the therapy of colon cancer.
    Welt S; Ritter G
    Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.
    Mitra S; Li G; Harsh GR
    Neurosurg Clin N Am; 2010 Jan; 21(1):67-76. PubMed ID: 19944967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
    Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor markers of the central nervous system: biological basis and clinical relevance.
    Birkmayer GD
    Cancer Detect Prev; 1983; 6(1-2):317-24. PubMed ID: 6883389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.
    Bourdon MA; Wikstrand CJ; Furthmayr H; Matthews TJ; Bigner DD
    Cancer Res; 1983 Jun; 43(6):2796-805. PubMed ID: 6342760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of antigenic expression of human glioma cells.
    McKeever PE; Davenport RD; Shakui P
    Crit Rev Neurobiol; 1991; 6(2):119-47. PubMed ID: 1934088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.
    Mizoguchi M; Betensky RA; Batchelor TT; Bernay DC; Louis DN; Nutt CL
    J Neuropathol Exp Neurol; 2006 Dec; 65(12):1181-8. PubMed ID: 17146292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
    Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
    Modak S; Gerald W; Cheung NK
    Med Pediatr Oncol; 2002 Dec; 39(6):547-51. PubMed ID: 12376975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
    Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
    Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
    Nicholas MK; Lukas RV; Jafri NF; Faoro L; Salgia R
    Clin Cancer Res; 2006 Dec; 12(24):7261-70. PubMed ID: 17189397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glial tumors of the brain: current aspects of their classification and bases for genetic predisposition].
    Anan'eva II; Malkarov MS; Korsakova NA; Balkanov AS; Dorofeev AE; Kachkov IA; Suchkov SV
    Arkh Patol; 2007; 69(1):54-60. PubMed ID: 19385137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
    Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
    Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
    Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
    J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.